Factors that individually predicted better prognosis were younger age (
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:OBJECTIVE A single-institution study of 7 years of experience was performed to investigate the clinicopathological and therapeutic characteristics of malignant pleural mesothelioma (MPM) patients who received multimodality treatment, as well as factors affecting survival.
📊
Temel Bulgular & Veri:METHODS A retrospective review of a consecutive cohort of pathologically confirmed MPM patients who were referred to our radiation oncology clinic and received multimodality treatment strategy that included surgery, chemotherapy, and radiotherapy at our training and research hospital between 2001 and 2008 was performed.
💡
Sonuç & Katkı:Factors that individually predicted better prognosis were younger age (
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2001 Verileri
⚙️Değişkenler:Alan Parametreleri
Abstract
OBJECTIVE A single-institution study of 7 years of experience was performed to investigate the clinicopathological and therapeutic characteristics of malignant pleural mesothelioma (MPM) patients who received multimodality treatment, as well as factors affecting survival. METHODS A retrospective review of a consecutive cohort of pathologically confirmed MPM patients who were referred to our radiation oncology clinic and received multimodality treatment strategy that included surgery, chemotherapy, and radiotherapy at our training and research hospital between 2001 and 2008 was performed. RESULTS A total of 53 patients were included in the study. Median age was 58 years (range: 33–79 years). Mean duration of follow-up was 14 months (range: 4–82 months). Disease-free status and overall survival were 11 months (range: 3–50 months) and 14 months (range: 4–82 months), respectively. Factors that individually predicted better prognosis were younger age (
🔖
Bu Makaleye Atıf Yap
ORUÇ, A. F., GÜL, Ş. K., ORUÇ, Ö. (2022). Clinicopathological and Survival Characteristics of Malignant Pleural Mesothelioma: A Single-Institutional Experience. Türk Onkoloji Dergisi, Cilt: 32 - Sayı: 1, 14–18. https://ajindex.com/articles/639281
Borasio P, Berruti A, Billé A, Lausi P, Levra MG, Giardino R, et al. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg 2008;33(2):307–13
Montanaro F, Rosato R, Gangemi M, Roberti S, Ricceri F, Merler E, et al. Survival of pleural malignant mesothelioma in Italy: a population-based study. Int J Cancer 2009;124(1):201–7
Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995;108(4):1122–8
Britton M. The epidemiology of mesothelioma. Semin Oncol 2002;29(1):18–25
Metintas M, Metintas S, Ak G, Erginel S, Alatas F, Kurt E, et al. Epidemiology of pleural mesothelioma in a population with non-occupational asbestos exposure. Respirology 2008;13(1):117–21
Metintas S, Metintas M, Ucgun I, Oner U. Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area. Chest 2002;122(6):2224–9
Senyiğit A, Bayram H, Babayiğit C, Topçu F, Nazaroğlu H, Bilici A, et al. Malignant pleural mesothelioma caused by environmental exposure to asbestos in the Southeast of Turkey: CT findings in 117 patients. Respiration 2000;67(6):615–22
Baris YI, Saracci R, Simonato L, Skidmore JW, Artvinli M. Malignant mesothelioma and radiological chest abnormalities in two villages in Central Turkey. An epidemiological and environmental investigation. Lancet 1981;1(8227):984–7
Mandira R, Hedy LK. Malignant Pleural Mesothelioma. Chest Sept 2009;136:3. 10.Adams VI, Unni KK, Muhm JR, Jett JR, Ilstrup DM, Bernatz PE. Diffuse malignant mesothelioma of pleura. Diagnosis and survival in 92 cases. Cancer 1986;58(7):1540–51. 11.Baris YI, Sahin AA, Ozesmi M, Kerse I, Ozen E, Kolacan B, et al. An outbreak of pleural mesothelioma and chronic fibrosing pleurisy in the village of Karain/ Urgüp in Anatolia. Thorax 1978;33(2):181–92. 12.Scagliotti GV, Novello S. State of the art in mesothelioma. Annals of Oncology 2005;16(supplement 2):240– 5. 13.Boutin C, Schlesser M, Frenay C, Astoul P. Malignant pleural mesothelioma. Eur Respir J 1998;12(4):972–81. 14.Sterman DH, Kaiser LR, Albelda SM. Advances in the treatment of malignant pleural mesothelioma. Chest 1999;116(2):504–20. 15.Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1996;111(4):815–26. 16.Ru